Clozapine is widely underused. No study has assessed views of patients suitable for, but not yet receiving, clozapine. We aimed to assess views of clozapine in patients eligible for clozapine but not yet prescribed it by conducting semistructured interviews with acutely unwell hospital in-patients. We interviewed 61 of 116 eligible patients and 50 (82%) answered all questions. At interview, 33 (54%) of 61 participants had heard of clozapine and 17 (30%) of 57 participants said they would take it if asked. Overall, 31 (57%) of 54 respondents said blood testing would not preclude them taking clozapine. The necessity for hospital admission was seen as the greatest barrier to receiving clozapine - 25 (49%) of 51 respondents stated this would be a reason for their refusing clozapine. Concerns about adverse effects of clozapine were considered sufficient to refuse clozapine in 23 (43.4%) of 53 respondents. Overall, 12 (24%) of 50 respondents felt that clozapine would be helpful to them. Patients' acceptance of clozapine is likely to be improved by offering the opportunity to start clozapine at home and by improved education about the therapeutic benefits of clozapine and the management of its adverse effects. Blood testing does not appear to be an important barrier to the initiation of clozapine.

中文翻译：

---

患者对开始使用氯氮平的态度。

氯氮平被广泛使用不足。没有研究评估过适合但尚未接受氯氮平的患者的观点。我们旨在通过对急性不适的住院患者进行半结构化访谈，评估符合使用氯氮平但尚未开处方的患者对氯氮平的看法。我们采访了 116 名符合条件的患者中的 61 名，其中 50 名（82%）回答了所有问题。在采访中，61 名参与者中有 33 名（54%）听说过氯氮平，57 名参与者中有 17 名（30%）表示如果被问到他们会服用。总体而言，54 名受访者中有 31 人（57%）表示血液检测不会排除他们服用氯氮平。住院的必要性被视为接受氯氮平的最大障碍——51 名受访者中有 25 人（49%）表示这将是他们拒绝氯氮平的原因。53 名受访者中有 23 人（43.4%）认为对氯氮平不良反应的担忧足以拒绝氯氮平。总体而言，50 名受访者中有 12 名（24%）认为氯氮平对他们有帮助。患者对氯氮平的接受度可能会通过提供在家中开始使用氯氮平的机会以及通过改进关于氯氮平的治疗益处及其不良反应管理的教育来提高。血液检测似乎不是开始使用氯氮平的重要障碍。通过提供在家中开始使用氯氮平的机会以及改进关于氯氮平的治疗益处及其不良反应管理的教育，可能会提高对氯氮平的接受度。血液检测似乎不是开始使用氯氮平的重要障碍。通过提供在家中开始使用氯氮平的机会以及改进关于氯氮平的治疗益处及其不良反应管理的教育，可能会提高对氯氮平的接受度。血液检测似乎不是开始使用氯氮平的重要障碍。